-
Mashup Score: 5Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS - 18 hour(s) ago
Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS - 5 day(s) ago
Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Treatment with nadofaragene firadenovec produced a high 3-month CR rate of 75% in patients with high-risk, BCG-unresponsive #NMIBC and CIS with or without papillary tumors. #BladderCancer https://t.co/C93ehvo5C2
-
-
Mashup Score: 3Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS - 26 day(s) ago
Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS #NMIBC #BladderCancer https://t.co/CDEix17ynv
-
-
Mashup Score: 6Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC - 1 month(s) ago
Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Data from a real-world study revealed that, at a median follow-up of 8.2 months, patients with #NMIBC who received nadofaragene firadenovec achieved a cystectomy-free survival rate of 95%. @MarkTysonMD @MayoClinic @MayoUrology #BladderCancer Read the Q&A: https://t.co/Qc4FloVUpf
-
-
Mashup Score: 4Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC - 1 month(s) ago
Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The favorable dosing schedule of nadofaragene firadenovec makes it a suitable option for patients with BCG-unresponsive #NMIBC who have to travel far for care. @MarkTysonMD @MayoClinic @MayoUrology #BladderCancer https://t.co/o9BQL2kVwz https://t.co/ZXdVtKgUKM
-
-
Mashup Score: 0Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage - Brian Chun - 1 year(s) ago
Ruchika Talwar hosts a conversation with Brian Chun to discuss Chun’s study on the impacts of the BCG drug shortage, a problem that has plagued urologists nationwide for nearly a decade, on the treatment of non-muscle invasive bladder cancer. Chun’s research, conducted through a review of Medicare claims data from 2010 to 2017, reveals a decrease in BCG use across the country and a considerable…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Variation in statewide intravesical treatment rates for #NMIBC during the BCG drug shortage. Brian Chun, MD @UPMC joins @RuchikaTalwarMD @VUMCurology to discuss his study and the importance of reducing dependence on single-source drugs > https://t.co/6cFBB2PahT #BladderCancer https://t.co/ReYr3e0XyB
-
-
Mashup Score: 0Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage - Brian Chun - 2 year(s) ago
Ruchika Talwar hosts a conversation with Brian Chun to discuss Chun’s study on the impacts of the BCG drug shortage, a problem that has plagued urologists nationwide for nearly a decade, on the treatment of non-muscle invasive bladder cancer. Chun’s research, conducted through a review of Medicare claims data from 2010 to 2017, reveals a decrease in BCG use across the country and a considerable…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Variation in statewide intravesical treatment rates for #NMIBC during the BCG drug shortage. Brian Chun, MD @UPMC joins @RuchikaTalwarMD @VUMCurology to discuss his study and the importance of reducing dependence on single-source drugs > https://t.co/6cFBB2PahT #BladderCancer https://t.co/ReYr3e0XyB
-
Treatment with nadofaragene firadenovec-vncg produced a high 3-month CR rate of 75% in patients with high-risk, BCG-unresponsive #NMIBC and CIS with or without papillary tumors. #BladderCancer https://t.co/sD6d1rilqR https://t.co/DKGh61fAnG